Navigation Links
Promising Phase 3 Trial Results Show Novel Biologic Therapy Ustekinumab (CNTO 1275) Significantly Improved Psoriasis
Date:10/3/2007

stekinumab would represent a much needed addition in the treatment armamentarium."

About the PHOENIX 2 Trial

The Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial Evaluating the Efficacy and Safety of CNTO 1275 in the Treatment of Subjects with Moderate to Severe Plaque-type Psoriasis Followed by Long-term Extension 2 (PHOENIX 2) trial involved 1,230 patients with chronic plaque psoriasis. Patients were randomized to receive subcutaneously administered ustekinumab or placebo. Patients randomized to receive ustekinumab received 45 mg or 90 mg doses at weeks 0 and 4 followed by the same dose every 12 weeks. Patients in the placebo group crossed over to receive either 45 mg or 90 mg doses of ustekinumab at weeks 12 and 16 and every subsequent 12 weeks. The primary end point of the study was the proportion of patients who achieved PASI 75 at week 12.

Through week 12, the placebo-controlled portion of the study, the percentages of study participants who experienced at least one adverse event (AE) were comparable between the placebo group (49 percent) and the ustekinumab 45 mg group (53 percent) and 90 mg group (48 percent). Discontinuation due to an AE occurred in 0.2 percent and one percent of patients in the respective ustekinumab groups, compared with two percent of patients in the placebo group. Two percent and one percent of patients receiving 45 mg or 90 mg ustekinumab, respectively, experienced at least one serious AE compared with two percent of patients receiving placebo.

About Psoriasis

Psoriasis is a chronic, immune-mediated disease that results from inflammation in the skin and overproduction of skin cells that accumulate on the surface causing red, scaly plaques that may itch and bleed. This chronic inflammation is driven in part by IL-12 and IL-23, cytokines involved in the regulation of the body's immune response. It is estimated that 125 million people worldwide have psoriasis, including two percent of
'/>"/>

SOURCE Centocor, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
2. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
3. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
4. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
5. Antisense Pharma: Promising Phase IIb Results of Targeted Therapy with AP 12009 in Recurrent Anaplastic Astrocytoma
6. Promising Data on Cognitive Effects of Safinamide in Early Parkinsons Disease
7. Promising Results with Epratuzumab and Chemotherapy in Children with Acute Lymphoblastic Leukemia
8. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
9. Investigational Cancer Drug Pertuzumab Shows Promising Results in Advanced Breast Cancer When Combined with Herceptin
10. Kosan Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Epothilone KOS-1584 at ASCO
11. Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing Promising Antitumor Activity in Multiple Myeloma at ASCO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... 30, 2015  Amgen (NASDAQ: AMGN ) today announced ... director of Warburg Pincus LLC, to the Amgen Board of ... Fred Hassan and the deep, global experience he brings ... Robert A. Bradway , chairman and chief executive officer of Amgen. ... serve Amgen well." Mr. Hassan has been Partner ...
(Date:7/30/2015)... LAKE, N.J. , July 30, 2015 ... simultaneously in the United States , ... the FDA, EMA and MHLW, respectively) for eribulin, for ... (STS) who have received prior chemotherapy for advanced or ... based on data from a pivotal global Phase 3 ...
(Date:7/30/2015)... 2015 P&S Market ... market overview, trends, DRO analysis, market segmentation, ... developments, competitive scenario and top competitor profiles ... Market Development and Demand Forecast to 2020  ... Explore more about global biosensors ...
Breaking Medicine Technology:Amgen Announces Appointment Of Fred Hassan To Board Of Directors 2Amgen Announces Appointment Of Fred Hassan To Board Of Directors 3Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 2Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 3Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 4Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 5Global Biosensors Market (Size of $12,964 Million in 2014) to Witness 10% CAGR During 2015 - 2020 2Global Biosensors Market (Size of $12,964 Million in 2014) to Witness 10% CAGR During 2015 - 2020 3Global Biosensors Market (Size of $12,964 Million in 2014) to Witness 10% CAGR During 2015 - 2020 4Global Biosensors Market (Size of $12,964 Million in 2014) to Witness 10% CAGR During 2015 - 2020 5
... Aug. 30, 2011 Luminex Corporation (Nasdaq: ... two upcoming investment conferences, the Morgan Stanley Global Healthcare ... scheduled to take place in New York City. ... Patrick J. Balthrop, president and chief executive officer, will ...
... REDWOOD CITY, Calif., Aug. 30, 2011 Pearl ... randomized, double-blind, Phase 2b, dose-ranging study of its ... a long-acting beta-2 agonist (LABA) compared to placebo ... All doses of FF MDI tested produced highly ...
Cached Medicine Technology:Luminex Corporation to Present at Upcoming Investment Conferences In September 2Pearl Therapeutics Announces Positive Results for Phase 2b Dose-Ranging Study of Formoterol MDI 2Pearl Therapeutics Announces Positive Results for Phase 2b Dose-Ranging Study of Formoterol MDI 3
(Date:8/1/2015)... Greenwich, CT (PRWEB) , ... August 01, 2015 ... ... Great Point Partners I, L.P. (“GPP”) portfolio company has acquired Premier Physical Therapy ... incorporating it into its portfolio of state-of-the-art clinics. , “Our acquisition of Premier ...
(Date:8/1/2015)... ... , ... On March 19, 2015 Phil Valentine – the Executive Director of Connecticut Community for ... by stepping off Springer Mountain and heading north. Since that day, Phil has hiked over ... was greeted by friends and family. He visited CCAR and left an inspirational message ...
(Date:7/31/2015)... ... 2015 , ... Super Bowl 50 will emanate from Levi’s Stadium in Santa Clara, ... is the Super Bowl. In the two weeks that separate the conference championships and the ... 2016 Super Bowl game will mark the 50th time it has been held and the ...
(Date:7/31/2015)... ... ... The 2nd annual Ride to Fight On will start and end near the ... to Fight On is a cycling fundraiser that benefits the West Cancer Center, a ... University of Tennessee Health Science Center. A health and wellness festival featuring food, music, ...
(Date:7/31/2015)... Mountain View, CA (PRWEB) , ... July 31, 2015 , ... ... hand for the athletes, judges, media, and VIPs at the 2015 Vans US Open ... best-tasting organic coconut water that can claim “no added sugar” on the market, is ...
Breaking Medicine News(10 mins):Health News:Professional Physical Therapy Now Largest Outpatient Physical Therapy Provider in Northeast With Acquisition of Premier Physical Therapy & Wellness 2Health News:Connecticut Executive Hikes Appalachian Trail to Raise Awareness About Recovery. 2Health News:Cheap 2016 Super Bowl Tickets at Levi's Stadium: Ticket Down Slashes Ticket Prices on Super Bowl 50 Tickets in Santa Clara, CA at Levi's Stadium 2Health News:West Cancer Center Announces 2nd Annual Ride to Fight On 2Health News:West Cancer Center Announces 2nd Annual Ride to Fight On 3Health News:Coco Libre Brings Eco-conscious Hydration to Vans US Open of Surfing 2
... ... Owens will be installed as the 86th president of the National Dental Association (NDA) at ... ... -- Nashville dentist Dr. Walter R. Owens will be installed as the 86th president of ...
... ... , ... (PRWEB) December 2, 2009 -- Perhaps the best medical advice to give consumers is ... keeping control of personal medical records is easier than ever. MyEMRChoice.com, a Fort Washington, ...
... ... medical device software engineering consulting firm Full Spectrum Software has received ... firms have actually achieved ISO 13485 certification. Many medical device makers ... well. However, it is somewhat rare for a medical device software ...
... Dec. 2 A randomized, controlled study comparing standard conservative ... for painful herniated disc revealed that while both treatments help ... pain free up to two years later. Results of the ... the annual meeting of the Radiological Society of North America ...
... CHICAGO Targeted breast ultrasound of suspicious areas of ... cost-effective alternative to invasive biopsies for women under age ... today at the annual meeting of the Radiological Society ... ultrasound, we can reduce the number of expensive and ...
... ... Ill. has become the state’s newest kidney transplant center and the first for Chicago’s ... by the Illinois Health Facilities and Services Review Board. , ... Springfield, Ill. (Vocus) -- Advocate Christ ...
Cached Medicine News:Health News:Meharry Medical College Officer Will Head the National Dental Association 2Health News:Meharry Medical College Officer Will Head the National Dental Association 3Health News:Personal Health Records On-Demand, In Your Pocket 2Health News:Medical Device Software Engineering Consulting firm Full Spectrum Software Earns ISO 13485 Certification 2Health News:Outpatient Disc Treatment Gives Long-Term Back Pain Relief 2Health News:Outpatient Disc Treatment Gives Long-Term Back Pain Relief 3Health News:Targeted breast ultrasound can reduce biopsies for women under 40 2Health News:State Approves Plans For Kidney Transplants At Advocate Christ Medical Center 2Health News:State Approves Plans For Kidney Transplants At Advocate Christ Medical Center 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: